AccuDial featured on T.V. show
HOLLYWOOD, Calif. AccuDial Pharmaceutical’s AccuDial product was featured Thursday afternoon on an episode of CBS’ “The Doctors” as one possible solution to a common problem facing parents — how much cough syrup should they give their children?
“Studies show that children are given an inaccurate dose of over-the-counter medication more than half the time by parents,” commented Dr. Jim Sears, a board certified pediatrician and one of the featured doctors on the program. “Pediatricians, we always dose by weight,” he said. “But a lot of the over-the-counter [medicines] give an age range — six to 12 years old — a huge range.”
Sears then held an AccuDial label up to the camera, explaining that the patented label could be rotated so that parents could determine proper dosage by weight. A dosage spoon is included with the medicine, Sears added.
Lansinoh, Teva make donations for Haiti earthquake relief
ALEXANDRIA, Va. A supplier of breast-feeding products and a drug maker are participating in providing relief to Haiti following a devestating earthquake that struck the country last week.
Lansinoh donated $10,000 to UNICEF in support of the organization’s disaster relief efforts, while Teva contributed more than $7 million in medicine to benefit earthquake victims in Haiti.
UNICEF was chosen for its support of breast-feeding in emergency situations, Lansinoh said.
“Breast-feeding support is crucial right now for the people of Haiti,” said Gina Ciagne, certified lactation counselor and director, breast-feeding and consumer relations with Lansinoh. “Breast-feeding is a safe, sanitary and reliable food source for the thousands of infants in danger. The devastation in Haiti calls for relief workers to support mothers in breast-feeding their babies, and protect them from disease and risk of malnourishment.”
- Breast milk is the ideal food for the healthy growth and development of children. It provides valuable protection from infections, which is all the more important in environments lacking adequate water supply and sanitation.
- Feeding such breast-milk substitutes as infant formula during emergencies offers no immune protection against diseases and poses health risks because mothers have to depend on the quality and supply of formula, water and fuel for preparation and cleaning of feeding bottles.
- Mothers also should be aware that they can increase their milk supply and relactate after having stopped breast-feeding.
“Our hearts go out to the tens of thousands of devastated Haitians,” said Gary Downing, CEO of Lansinoh. “We’re encouraging others to donate what they can to UNICEF and the Haiti disaster relief efforts. There is no better time to make a small sacrifice for those who are in need.”
Meanwhile, Teva said it is working with several of its nongovernmental organization partners to ensure these drugs are delivered to Haiti without delay.
“As a company, Teva was devastated to hear about the earthquake, and our hearts and thoughts go out to the country of Haiti,” said Shlomo Yanai, Teva’s president and CEO. “Working with our partners, we are providing essential medical products to assist in the relief efforts.”
Alcon criticizes Novartis’ acquisition offer
HUNENBERG, Switzerland Alcon has seen Novartis’ acquisition offer, and it is not impressed.
Novartis announced Jan. 4 that it would acquire a 77% stake in the Swiss eye-care company for $38.5 billion, but an Alcon independent director committee called that amount “grossly inadequate” and said Novartis’ tactics were “coercive” and “offensive.” The Novartis proposal would distribute much of Alcon’s value to its two largest shareholders, though many of Alcon’s minority shareholders have been long-term investors in the company since its 2002 initial public offering or are employees of the company.
“Advocates of sound corporate governance and well-established principles of fairness and equity in both Switzerland and the U.S. are rightly offended by Novartis’ coercive attempts to take advantage of the Alcon minority shareholders,” committee chairman Thomas Plaskett said in a statement. “The committee will evaluate and take all appropriate and available steps to ensure that the rights of Alcon’s minority shareholders are not trampled on in the manner proposed by Novartis.”
UPDATE: A Novartis spokesman told Drug Store News Friday that the company declined to comment on the matter.